NYSEAMERICAN:BPMXBiopharmx Stock Price, Forecast & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biopharmx in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Biopharmx.

Biopharmx is scheduled to release its next quarterly earnings announcement on Tuesday, June 9th 2020. View our earnings forecast for Biopharmx.

Biopharmx Corp (NYSEAMERICAN:BPMX) posted its quarterly earnings data on Tuesday, December, 10th. The biotechnology company reported ($1.68) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($2.64) by $0.96. View Biopharmx's earnings history.

Shares of Biopharmx reverse split before market open on Tuesday, May 19th 2020. The 1-12 reverse split was announced on Friday, May 15th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 18th 2020. An investor that had 100 shares of Biopharmx stock prior to the reverse split would have 8 shares after the split.

1 brokerages have issued 12 month target prices for Biopharmx's shares. Their forecasts range from $12.00 to $12.00. On average, they expect Biopharmx's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 312.4% from the stock's current price. View analysts' price targets for Biopharmx.

Media coverage about BPMX stock has been trending extremely negative recently, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Biopharmx earned a media sentiment score of -4.5 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near future. View the latest news aboutBiopharmx.

Some companies that are related to Biopharmx include IMV (IMV), Medicenna Therapeutics (MDNA), Emblem (EMC), Exicure (XCUR), Novacyt (NCYT), Fennec Pharmaceuticals (FRX), Pfenex (PFNX), Theratechnologies (TH), Bioventix (BVXP), Exicure (XCUR), Enochian Biosciences (ENOB), Antibe Therapeutics (ATE), OncoCyte (OCX), IMV (IMV) and Rafael (RFL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Biopharmx investors own include Sarepta Therapeutics (SRPT), Netlist (NLST), Neovasc (NVCN), Hawkins (HWKN), Novavax (NVAX), CytRx (CYTR), Protalix Biotherapeutics (PLX), Synergy Pharmaceuticals (SGYP), AVEO Pharmaceuticals (AVEO) and Rexahn Pharmaceuticals (REXN).

Biopharmx trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BPMX."

Shares of BPMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BPMX stock can currently be purchased for approximately $2.91.

Biopharmx has a market capitalization of $53.19 million. Biopharmx employs 17 workers across the globe.

The official website for Biopharmx is www.biopharmx.com.

Biopharmx's mailing address is 1505 Adams Dr Ste D, MENLO PARK, CA 94025-1451, United States. The biotechnology company can be reached via phone at +1-650-8895020.